@article{e59e8942eb6544e3a6c960e6717aad67,
title = "Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease",
abstract = "Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P <.001 and OR = 1.81; 95% CI = 1.16-2.82; P =.009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to increase risk. Lp-PLA2 was absent from the brain tissue in both groups. Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-PLA2 with AD may be mediated through vascular damage.",
keywords = "Alzheimer's disease, Biomarkers, Dementia, Homocysteine, Lp-PLA2",
author = "{Texas Alzheimer's Disease Research and Care Consortium} and Doody, {Rachelle S.} and Jasenka Demirovic and Ballantyne, {Christie M.} and Wenyaw Chan and Robert Barber and Suzanne Powell and Valory Pavlik and Susan Rountree and Paul Massman and Eveleen Darby and Tracy Evans and Aisha Khaleeq and Gregory Schrimsher and Andrew Dentino and Ronnie Orozco and Thomas Fairchild and Janice Knebl and O'Bryant, {Sid E.} and Hall, {James R.} and Douglas Mains and Lisa Alvarez and Erin Braddock and Rosemary McCallum and Leigh Johnson and Perrie Adams and Roger Rosenberg and Myron Weiner and Benjamin Williams and Mary Quiceno and Joan Reisch and Ryan Huebinger and Guanghua Xiao and Doris Svetlik and Amy Werry and Janet Smith and Donald Royall and Raymond Palmer and Marsha Polk",
note = "Funding Information: R.S.D. served as an ad hoc consultant to AbbVie, Accera, Avanir, Banner Health, Baxter, BioTE, Cardeus, Chiesi, Genzyme, Hoffman-La Roche, Merck, Novartis, NeuroCog, Nutricia, Pfizer, QR Pharma, Shire, Sonexa, Suven, Targacept, Takeda, and Toyoma. She is on the Scientific Advisory Boards of AC Immune, AZ Therapies, CereSpir, and QR Pharma and on a Data Safety Monitoring committee for Hoffman-La Roche. She is the principal investigator on clinical trials funded by Accera, Avanir, Genentech, Merck, Pfizer, and Takeda and holds stock options in AZ Therapies, QR Pharma, Sonexa, and Transition. She receives support from the NIH funded Alzheimer's Disease Cooperative study for chairing a committee, and for clinical trials, and receives support from the NIH funded Alzheimer's Disease Neuroimaging Initiative. She is coinvestigator on NIH 1UF1AGO46143. C.M.B. served on scientific advisory boards for Pfizer; Merck; the Council on Atherosclerosis, Thrombosis, and Vascular Biology; and the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. He is on the Data Safety Monitoring Board for the NHLBI Cardiovascular Inflammation Reduction Trial. He holds a patent on “Non-Human Animal Having Predefined Allele of Cellular Adhesion Gene” and a provisional patient “Biomarkers to Improve Prediction of Heart Failure Risk.” He receives royalties from the book Clinical Lipidology: a Companion to Braunwald's Heart Disease. He has received honoraria for speaking for Abbott and is on the speakers' bureaus for Abbott, GlaxoSmithKline, and Merck. He has consulted for Abbott, AdNexus, Aegerion, Amarin, Amgen, Amylin, Arena, AstraZeneca, Bristol-Myers-Squibb, Cerenis, Esperior, Genentech, Genzyme, GlaxoSmithKline, Idera, Kowa, Merck, Novartis, Omthera, Pfizer, Regeneron, Resverlogix, Roche, Sanofi-Synthelabo, and Takeda. R.B. has received travel expenses and honoraria for lectures and educational activities not funded by industry and has a patent pending on “Methods and devices for diagnosing AD” patent #13/697,978. S.P. is an editor for Modern Pathology and Archive of Pathology & Laboratory Medicine. She has received honoraria for speaking at academic institutions. V.P. is a subinvestigator on a study supported by Takeda, was principal investigator on an AHRQ funded grant and is coinvestigator on another, and was coinvestigator on an NHLBI grant. J.D. and W.C. report no disclosures. Funding Information: The authors acknowledge that this project was supported by the Texas Alzheimer's Research and Care Consortium (TARCC) funded by the State of Texas through the Texas Council on Alzheimer's Disease and Related Disorders . ",
year = "2015",
month = dec,
day = "1",
doi = "10.1016/j.dadm.2015.08.001",
language = "English (US)",
volume = "1",
pages = "464--471",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "4",
}